CROSSJECTCROSSJECTCROSSJECT

CROSSJECT

No trades
See on Supercharts
Market capitalization
‪74.12 M‬EUR
−0.230EUR
‪−8.47 M‬EUR
‪22.04 M‬
Beta (1Y)
1.39

About CROSSJECT

CEO
Patrick Alexandre
Headquarters
Dijon
Founded
2001
ISIN
FR0011716265
FIGI
BBG005YTKZ16
Crossject SA manufactures and markets needle free injection system. It develops and produces generic drugs such as methotrexate, epinephrin, and sumatriptan. The company distributes its products under the Zeneo brand. Crossject was founded by Patrick Alexandre and Xavière Castano on August 8, 2001 and is headquartered in Dijon, France.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of ALCJ is 2.060 EUR — it has increased by 0.98% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on EURONEXT exchange CROSSJECT stocks are traded under the ticker ALCJ.
ALCJ stock is 7.11% volatile and has beta coefficient of 1.39. Check out the list of the most volatile stocks — is CROSSJECT there?
One year price forecast for CROSSJECT has a max estimate of 5.000 EUR and a min estimate of 4.400 EUR.
Yes, you can track CROSSJECT financials in yearly and quarterly reports right on TradingView.
ALCJ stock has fallen by 0.48% compared to the previous week, the month change is a 37.58% fall, over the last year CROSSJECT has showed a 45.79% decrease.
ALCJ net income for the last quarter is ‪−3.91 M‬ EUR, while the quarter before that showed ‪−4.56 M‬ EUR of net income which accounts for 14.40% change. Track more CROSSJECT financial stats to get the full picture.
Today CROSSJECT has the market capitalization of ‪74.16 M‬, it has decreased by 28.89% over the last week.
No, ALCJ doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ALCJ shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CROSSJECT stock right from TradingView charts — choose your broker and connect to your account.
ALCJ reached its all-time high on Feb 25, 2014 with the price of 13.015 EUR, and its all-time low was 1.015 EUR and was reached on Dec 28, 2018.
See other stocks reaching their highest and lowest prices.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CROSSJECT technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CROSSJECT stock shows the strong sell signal. See more of CROSSJECT technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on CROSSJECT future price: according to them, ALCJ price has a max estimate of 5.00 EUR and a min estimate of 4.40 EUR. Read a more detailed CROSSJECT forecast: see what analysts think of CROSSJECT and suggest that you do with its stocks.